Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
159
Views
30
CrossRef citations to date
0
Altmetric
Review

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

V Di Lernia1 Dermatology Unit, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, ItalyCorrespondence[email protected]
&
F Bardazzi2 Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
Pages 533-539 | Published online: 29 Jan 2016

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Eckart Haneke. (2017) Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis: Targets and Therapy 7, pages 51-63.
Read now
Aniseh Samadi, Saman Ahmad Nasrollahi, Ashkan Hashemi, Mansour Nassiri Kashani & Alireza Firooz. (2017) Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. Journal of Dermatological Treatment 28:6, pages 476-483.
Read now
Ramya Vangipuram & Ali Alikhan. (2017) Apremilast for the management of moderate to severe plaque psoriasis. Expert Review of Clinical Pharmacology 10:4, pages 349-360.
Read now
M. Galluzzo, S. D’Adamio, S. Servoli, L. Bianchi, S. Chimenti & M. Talamonti. (2016) Tofacitinib for the treatment of psoriasis. Expert Opinion on Pharmacotherapy 17:10, pages 1421-1433.
Read now

Articles from other publishers (26)

Jiaming He, Minghui Zhao, Xiaoyu Ma, Dilong Li, Jingyan Kong & Fan Yang. (2023) The role and application of three IFN-related reactions in psoriasis. Biomedicine & Pharmacotherapy 167, pages 115603.
Crossref
Masoud Mardani, Jafar Mohammadshahi, Sara abolghasemi & Roghayeh Teimourpour. (2023) Drug-induced liver injury due to tofacitinib: a case report. Journal of Medical Case Reports 17:1.
Crossref
Amruta A. Dandekar, Harsha T. Garimella, Carrie L. German & Ajay K. Banga. (2022) Microneedle Mediated Iontophoretic Delivery of Tofacitinib Citrate. Pharmaceutical Research 40:3, pages 735-747.
Crossref
Krisztina Pohóczky, József Kun, Nikolett Szentes, Tímea Aczél, Péter Urbán, Attila Gyenesei, Kata Bölcskei, Éva Szőke, Serena Sensi, Ádám Dénes, Andreas Goebel, Valéria Tékus & Zsuzsanna Helyes. (2022) Discovery of novel targets in a complex regional pain syndrome mouse model by transcriptomics: TNF and JAK-STAT pathways. Pharmacological Research 182, pages 106347.
Crossref
Jingwen Deng, Carlotta Schieler, José A. M. Borghans, Chuanjian Lu & Aridaman Pandit. (2022) Finding Gene Regulatory Networks in Psoriasis: Application of a Tree-Based Machine Learning Approach. Frontiers in Immunology 13.
Crossref
Nilgün Şentürk. (2022) Tofacitinib. TURKDERM, pages 67-69.
Crossref
Inessa Mykhailivna Serbina & Yu. S. Ovcharenko. (2021) JANUS KINASE INHIBITORS IN DERMATOLOGY: PRESENT AND FUTURE. International Medical Journal:4(108), pages 70-76.
Crossref
Lihua Hao, Yuancheng Mao, Jin Park, Eun Ju Bae & Byung‐Hyun Park. (2021) Repurposing the anthelmintic praziquantel to treat psoriasis. British Journal of Pharmacology 178:23, pages 4726-4740.
Crossref
Lihua Hao, Yuancheng Mao, Jin Park, Byoung-Mog Kwon, Eun Ju Bae & Byung-Hyun Park. (2021) 2′-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice. Experimental & Molecular Medicine 53:5, pages 875-884.
Crossref
Sonal Muzumdar, Craig Leonardi & Bruce Strober. (2021) Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. Journal of Psoriasis and Psoriatic Arthritis 6:2, pages 93-98.
Crossref
Khadiga S. Sayed, Mohamed H.M. EL-Komy, Hany Shehata, Sarah H. ElShazly, Eman D. El Desouky, Khalda Sayed Amr, Nesma M. ElAraby & Aya M. AlOrbani. (2020) <b><i>JAK1</i></b> rs310241 and <b><i>JAK3</i></b> rs3008 Genotypes May Increase Susceptibility to Psoriasis: A Case Control Study. Skin Pharmacology and Physiology 33:4, pages 207-212.
Crossref
M. Boyadzhiev, L. Marinov, V. Boyadzhiev, V. Iotova, I. Aksentijevich & S. Hambleton. (2019) Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome. Pediatric Rheumatology 17:1.
Crossref
Fei Yi, Xiaoli Zheng, Fang Fang, Jiaan Zhang, Bingrong Zhou & Xiangsheng Chen. (2019) ALA‐PDT alleviates the psoriasis by inhibiting JAK signalling pathway. Experimental Dermatology 28:11, pages 1227-1236.
Crossref
Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke & David S. Weinstein. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry 62:20, pages 8973-8995.
Crossref
Yesim Akpinar Kara. 2019. Tailored Treatments in Psoriatic Patients. Tailored Treatments in Psoriatic Patients.
Martina Morelli, Claudia Scarponi, Laura Mercurio, Francesco Facchiano, Sabatino Pallotta, Stefania Madonna, Giampiero Girolomoni & Cristina Albanesi. (2018) Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Journal of Immunology Research 2018, pages 1-18.
Crossref
Charles J. Malemud. (2018) Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases. Current Pharmacology Reports 4:5, pages 358-366.
Crossref
Alexandra Azevedo & Tiago Torres. (2017) Tofacitinib: A New Oral Therapy for Psoriasis. Clinical Drug Investigation 38:2, pages 101-112.
Crossref
Enzo Calautti, Lidia Avalle & Valeria Poli. (2018) Psoriasis: A STAT3-Centric View. International Journal of Molecular Sciences 19:1, pages 171.
Crossref
Hanan Rabea Nada, Dina Ahmed El Sharkawy, Maha Fathy Elmasry, Laila Ahmed Rashed & Sally Mamdouh. (2017) Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case–control study. Archives of Dermatological Research 310:1, pages 39-46.
Crossref
Masutaka Furue, Takahito Chiba, Gaku Tsuji, Dugarmaa Ulzii, Makiko Kido-Nakahara, Takeshi Nakahara & Takafumi Kadono. (2017) Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergology International 66:3, pages 398-403.
Crossref
Jennifer L. Seyffert & Owen N. Kramer. (2017) Review of the role of Janus kinase inhibitors in dermatology. Journal of the Egyptian Womenʼs Dermatologic Society 14:2, pages 73-75.
Crossref
William Damsky & Brett A. King. (2017) JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology 76:4, pages 736-744.
Crossref
J. Seneschal. (2016) Quoi de neuf en recherche dermatologique ?. Annales de Dermatologie et de Vénéréologie 143, pages S19-S22.
Crossref
Ulrich Amon & Raul Yaguboglu. (2016) Von der topischen Therapie bis zum Melanozytentransfer. hautnah dermatologie 32:5, pages 44-51.
Crossref
Vito Di Lernia. (2016) Targeting the IFN-γ/CXCL10 pathway in lichen planus. Medical Hypotheses 92, pages 60-61.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.